[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608193":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":24,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Beijing GoBroad Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Maintenance Therapy Group",null,[12],"Drug: Maintenance Therapy Group",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":10},"DRUG","Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"kai Hu","CONTACT","15810245863","hk13610956245@163.com",{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Kai Hu","Director of the Lymphoma Department at Beijing Gao Bo Hospital","100608193","exploratory-study-on-the-efficacy-of-zebutinib-as-maintenance-therapy-following-car-t-cell-therapy-in-patients-with-non-hodgkin-b-cell-lymphoma-100608193",false,"NCT07198373","Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age ≥ 18 years, no gender restrictions; (2) Expected survival time exceeding 12 weeks; (3) Cytologically or histopathologically confirmed diagnosis of non-Hodgkin B-cell lymphoma according to WHO 2016 criteria; (4) Platelet count ≥ 50 × 10⁹\u002FL; (5) Currently undergoing or scheduled to initiate oral zanubrutinib maintenance therapy following autologous or allogeneic CAR-T cell therapy; (6) Able to understand this trial and has signed an informed consent form.\n\nExclusion Criteria:\n\n* (1) Pregnant or lactating individuals; male subjects planning to conceive within one year of treatment or within one year after cell reinfusion, or whose partners plan to conceive within one year after cell reinfusion; (2) Individuals with medical conditions that affect their ability to sign a written informed consent form or comply with study procedures; or those unwilling or unable to adhere to study requirements; (3) Individuals deemed unsuitable for participation in this trial by the investigator.\n\n  1. Pregnant or lactating individuals; or male subjects planning to conceive within one year of treatment or within one year after cell infusion, or whose partners plan to conceive within one year after cell infusion; (2) Individuals with medical conditions that prevent signing a written informed consent form or complying with study procedures; or those unwilling or unable to comply with study requirements; (3) Individuals deemed unsuitable for this trial by the investigator.","ALL","18 Years",{"count":37,"type":38},40,"ESTIMATED","OBSERVATIONAL","This study is a single-center, Phase IV clinical trial designed to collect and analyze data on the efficacy and safety of zanubrutinib as maintenance therapy following CAR-T cell therapy in subjects with non-Hodgkin B-cell lymphoma.",[42],"B Cell Lymphoma","NOT_YET_RECRUITING","2025-09-21",{"date":46,"type":47},"2025-09-30","ACTUAL",{"date":49,"type":38},"2025-09-20",{"date":51,"type":38},"2028-12-30",{"name":5,"class":6}]